VIDEO: Smart Stop trial targeted combo for lymphoma potentially reduces chemotherapy need
Click Here to Manage Email Alerts
In this video, Jason Westin, MD, discusses the results of the Smart Stop trial, presented at ASH Annual Meeting and Exposition.
The research evaluated the effects of lenalidomide, tafasitamab (Monjuvi; Morphosys. Incyte), rituximab and acalabrutinib alone and with combination chemotherapy in patients with newly diagnosed diffuse large B-cell lymphoma.
"We found that four cycles of the targeted therapy combination — lenalidomide, tafasitamab, rituximab and acalabrutinib, or LTRA — resulted in a complete response rate of 63% and overall response rate of 100% prior to any chemo,” Westin, director of the lymphoma clinical research program at The University of Texas MD Anderson Cancer Center, said.
"So very intriguing as a potential way to deescalate or remove chemotherapy,” he said.
Reference:
- Westin J, et al. Abstract 856. Presented at: ASH Annual Meeting and Exposition, Dec. 9-12, 2023; San Diego.
Collapse
Healio Interviews
Click Here to Manage Email Alerts